Searched for
DRL EARNINGS
Dr Reddy's Q3 Results: Net profit rises 11% YoY to Rs 1,379 crore, meets estimatesDRL Q3 Results: The profit was slightly above the ET Now poll estimate of Rs 1,337 crore. Revenue from operations increased 7% year-on-year...- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Dr Reddy’s Q2 Preview: High base to play spoilsport, outlook for US, Russia in focusDr Reddy’s topline will continue to be aided by sales contributions from the cancer drug Revlimid’s generic. While the overall revenue grow...
- What CLSA says on Lupin; Morgan Stanley on DRL, Godrej ConsumerIn the case of DRL, Morgan Stanley said that the drug maker continued to deliver granular growth and that the growth trend should continue ...
- Dr Reddy's Labs Q4 Results: Consolidated profit tanks 76% YoY to Rs 88 croreThe profit figure was sharply lower compared with an ET Now analysts’ poll projection of Rs 560 crore.
- DRL Q3 Results: Drugmaker posts 25 times rise in PAT at Rs 709 cr, in line with estimatesThe revenue from operations came in at Rs 5,103 crore, up 8.3 per cent against Rs 4,711 crore in the corresponding quarter last year.
- DRL Q3 Results Preview: Profit may grow 25% YoY; margin likely to fallEdelweiss sess profit rising 26.5 per cent YoY to Rs 780 crore. It sees sales rising 12.2 per cent YoY to Rs 5,531 crore. The brokerage see...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- No Chinese supply threat for drug companies, but scaling Great Wall is tough“The concerns over supply of Chinese raw material proved to be ill-founded,” Nilesh Gupta, managing director of Lupin, told ET.
- Dr Reddy’s Laboratories: Long-term prospects look good despite hiccup in Q1DRL’s contract research and manufacturing business also posted subdued sales, showing just a 6% growth, due to fewer launches by DRL’s clie...
- Why does Dr Reddys labs commands much lower valuations than other pharma companies?The Hyderabad-based drug company has witnessed volatility in its performance on account of variety of reasons like periodical drug exclusiv...
- Dr Reddy's Labs: Stock presents a high-risk, high-growth bet for investorsDr Reddys Labs' fourth quarter results were better than expected. The market responded positively to this with the stock closing higher at ...
- US court ruling is what the doctor ordered for Dr Reddy's LabsA good show in the third quarter aside, a district court ruling in the US has now come as a shot in the arm for Dr Reddy's Labs, or DRL.
- Growth in US, local market to pep up DRLDr Reddy’s Laboratories (DRL), India’s third-largest pharma company, has seen a sharp rise of 25% in its stock price over the past fifteen ...
- GSK drug-deal talk lifts DRL scripShares of Dr Reddy’s Laboratories (DRL) touched an intra-day high of Rs 878.70, amid speculation that the Indian drug maker is in prelimina...
- Dr Reddy’s Lab embroiled in patent infringement row with AMRINYSE listed Dr Reddy’s Laboratories (DRL), India’s second largest company by revenue, is embroiled in a fresh patent infringement row with ...
- DRL faces patent suit in US over allergy genericNYSE-listed Dr Reddy’s Laboratories (DRL) is embroiled in a fresh patent infringement row with US-based drug-discovery firm Albany Molecula...
- Citigroup assigns 'hold' rating to Dr Reddy's LaboratoriesCitigroup has assigned a ‘hold’rating to Dr Reddy’s Laboratories (DRL) with a price target of Rs 547.
- Analyst's Pick: Dr Reddy's LaboratoriesCitigroup recommends 'Hold' rating on Dr Reddy’s Laboratories with a target price of Rs 547.
- Dr Reddy's trims non-US operationsThe company is trimming operations in many CIS countries, in the Middle East and Africa.
Load More
